PE20091717A1 - Pirido[3,4-b] indoles como moduladores de receptores de histamina - Google Patents

Pirido[3,4-b] indoles como moduladores de receptores de histamina

Info

Publication number
PE20091717A1
PE20091717A1 PE2009000435A PE2009000435A PE20091717A1 PE 20091717 A1 PE20091717 A1 PE 20091717A1 PE 2009000435 A PE2009000435 A PE 2009000435A PE 2009000435 A PE2009000435 A PE 2009000435A PE 20091717 A1 PE20091717 A1 PE 20091717A1
Authority
PE
Peru
Prior art keywords
alkyl
indol
tetrahydro
receptor modulators
histamine receptor
Prior art date
Application number
PE2009000435A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Asher Protter
David T Hung
Sarvajit Chakravarty
Rajendra Parasmal Jain
Sundeep Dugar
Original Assignee
Medivation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies Inc filed Critical Medivation Technologies Inc
Publication of PE20091717A1 publication Critical patent/PE20091717A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2009000435A 2008-03-24 2009-03-24 Pirido[3,4-b] indoles como moduladores de receptores de histamina PE20091717A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3905608P 2008-03-24 2008-03-24
US14507909P 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
PE20091717A1 true PE20091717A1 (es) 2009-11-25

Family

ID=40810809

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000435A PE20091717A1 (es) 2008-03-24 2009-03-24 Pirido[3,4-b] indoles como moduladores de receptores de histamina

Country Status (12)

Country Link
US (5) US8338447B2 (enExample)
EP (1) EP2280968A2 (enExample)
JP (2) JP5679538B2 (enExample)
CN (2) CN102083830B (enExample)
AR (1) AR071285A1 (enExample)
AU (1) AU2009228398B2 (enExample)
BR (1) BRPI0906244A2 (enExample)
CA (1) CA2719412A1 (enExample)
CL (1) CL2009000724A1 (enExample)
PE (1) PE20091717A1 (enExample)
TW (1) TWI443098B (enExample)
WO (1) WO2009120717A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2145887B1 (en) * 2007-04-05 2016-04-27 Alla Chem, LLC. Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indoles, methods for the production and use thereof
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
PE20091820A1 (es) 2008-03-24 2009-12-10 Medivation Technologies Inc Compuestos heterociclicos con uniones puente y metodos para usarlos
WO2009120717A2 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
US9063126B2 (en) 2008-09-29 2015-06-23 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
AR073924A1 (es) * 2008-10-31 2010-12-09 Medivation Technologies Inc Azepino[4, 5-b]indoles, una composicion farmaceutica y kits que los comprenden y su uso en la modulacion de un receptor de histamina.
AU2009308706C1 (en) * 2008-10-31 2016-01-21 Medivation Technologies, Inc. Pyrido (4,3-b) indoles containing rigid moieties
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
SG173639A1 (en) * 2009-02-11 2011-09-29 Sunovion Pharmaceuticals Inc Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011019417A1 (en) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
CN102480955B (zh) 2009-04-29 2015-08-05 梅迪维新技术公司 吡啶并[4,3-b]吲哚类和使用方法
CA2772525A1 (en) * 2009-09-11 2011-03-17 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
CA2775216A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
CN102711468B (zh) 2009-09-23 2014-07-09 梅迪维新技术公司 吡啶并[4，3-b]吲哚化合物及其使用方法
CA2775129A1 (en) * 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
WO2011038163A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103487A1 (en) * 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103433A1 (en) * 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103430A1 (en) * 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2012006419A2 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8815843B2 (en) 2011-02-18 2014-08-26 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012112964A2 (en) * 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012112963A1 (en) * 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US8796272B2 (en) * 2011-02-21 2014-08-05 Taisho Pharmaceutical Co., Ltd Glycine transporter-inhibiting substances
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
US20150315188A1 (en) * 2012-08-22 2015-11-05 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
EP2887803A4 (en) 2012-08-24 2016-08-03 Univ Texas PRO-NEUROGENIC COMPOUNDS
US10394936B2 (en) * 2012-11-06 2019-08-27 International Business Machines Corporation Viewing hierarchical document summaries using tag clouds
US9902713B2 (en) 2013-11-11 2018-02-27 Board Of Regents Of The University Of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
US12343337B2 (en) 2016-09-29 2025-07-01 The Regents Of The University Of California Compounds for increasing neural plasticity
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
US12083114B2 (en) 2018-12-19 2024-09-10 Disarm Therapeutics, Inc. Inhibitors of SARM1 in combination with neuro-protective agents
JP7636796B2 (ja) 2019-02-27 2025-02-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 脳障害を治療するためのｎ－置換インドール及び他の複素環化合物
EP3931189B1 (en) 2019-02-27 2025-12-24 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
PL3938047T3 (pl) 2019-03-22 2022-11-07 Gilead Sciences, Inc. Zmostkowane tricykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
EP4165042A4 (en) * 2020-06-10 2024-05-29 Delix Therapeutics, Inc. TRICYCLIC PSYCHOPLASTOGENS AND USES THEREOF
US12421235B2 (en) 2020-09-30 2025-09-23 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
PL4196479T3 (pl) 2021-01-19 2024-03-18 Gilead Sciences, Inc. Podstawione związki pirydotriazynowe i ich zastosowania
WO2023114313A1 (en) 2021-12-15 2023-06-22 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof
CN114539250B (zh) * 2022-03-04 2023-08-29 上海裕兰生物科技有限公司 一种阿尔兹海默症PET-tau示踪剂的制备方法
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
CN116751197B (zh) * 2023-03-27 2024-04-12 中国科学院昆明植物研究所 卡波林生物碱或其药学上可接受的盐及其制备方法和应用、卡波林生物碱药物组合物及应用
WO2024220485A2 (en) * 2023-04-18 2024-10-24 The Regents Of The University Of California Dual inhibitors of dyrk1a and 5-ht2 for treating a brain disorder

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642438A (en) * 1949-07-15 1953-06-16 Hoffmann La Roche Pyridindoles and method of manufacture
GB721171A (en) * 1951-04-30 1954-12-29 Bayer Ag Derivatives of ª‰- and ª†- carbolines
JPS3920857B1 (enExample) 1962-05-17 1964-09-24
JPS412713B1 (enExample) 1963-08-30 1966-02-21
DE3240511A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur herstellung von ss-carbolinderivaten
US4754038A (en) * 1987-02-26 1988-06-28 American Home Products Corporation Carboline histamine H1 antagonists
US5817756A (en) 1993-09-09 1998-10-06 Scios Inc. Pseudo- and non-peptide bradykinin receptor antagonists
WO1995007294A1 (en) 1993-09-09 1995-03-16 Scios Nova Inc. Pseudo- and non-peptide bradykinin receptor antagonists
US5688807A (en) 1994-03-11 1997-11-18 Eli Lilly And Company Method for treating 5HT2B receptor related conditions
CN1148340A (zh) 1994-03-11 1997-04-23 伊莱利利公司 治疗与5htzb受体有关病症的方法
US5631265A (en) 1994-03-11 1997-05-20 Eli Lilly And Company 8-substituted tetrahydro-beta-carbolines
DE69623610T2 (de) 1995-05-05 2003-02-20 British Technology Group Inter-Corporate Licensing Ltd., London Neue heterozyklische chemie
RU2140417C1 (ru) 1995-10-17 1999-10-27 Институт физиологически активных веществ РАН Производные гидрированных пиридо(4,3-b)индолов, способы их получения, фармацевтическая композиция и способ лечения
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
GB9604996D0 (en) 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
WO1997037658A1 (en) 1996-04-04 1997-10-16 F.Hoffmann-La Roche Ag Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
JP2001522884A (ja) 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法
FR2771095B1 (fr) 1997-11-14 1999-12-17 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE290527T1 (de) 1997-12-25 2005-03-15 Meiji Seika Kaisha Tetrahydrobenzindol-derivate
FR2796644B1 (fr) 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US20060235012A1 (en) 2003-06-16 2006-10-19 Chroma Therapeutics Limited Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
US7872133B2 (en) 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
US20070134733A1 (en) 2003-07-10 2007-06-14 Parallax Biosystems, Inc. Raman signature probes and their use in the detection and imaging of molecular processes and structures
RU2283108C2 (ru) 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20070179174A1 (en) 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
EP1714961B1 (en) 2004-02-12 2015-12-09 Mitsubishi Tanabe Pharma Corporation Indazole compound and pharmaceutical use thereof
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2006011750A1 (en) 2004-07-27 2006-02-02 C & C Research Laboratories Tetrahydro-beta-carbolinone derivatives and process for preparing the same
JP2008530136A (ja) 2005-02-14 2008-08-07 ミイカナ セラピューティクス インコーポレイテッド ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物
WO2007007072A1 (en) 2005-07-07 2007-01-18 Bio-Medisinsk Innovasjon As 5-htx modulators
EP1747779A1 (en) 2005-07-28 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Tetrahydro-b-carbolin-sulfonamide derivatives as 5-HT6 ligands
US20070117835A1 (en) 2005-10-04 2007-05-24 David Hung Methods and compositions for treating Huntington's disease
RU2338537C2 (ru) 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US20090247546A1 (en) * 2006-02-28 2009-10-01 Boehringer Ingelheim International Gmbh Treatment of Prevention of Valvular Heart Disease with Flibanserin
CA2664098A1 (en) 2006-09-20 2008-03-27 Medivation Neurology, Inc. Compounds and method for treating canine cognitive dysfunction syndrome
US20100099700A1 (en) 2006-09-20 2010-04-22 David Hung Hydrogenated pyrido (4,3-b) indoles for treating amyotrophic lateral sclerosis (als)
KR20090087009A (ko) 2006-10-27 2009-08-14 메디베이션 뉴롤로지 인코퍼레이티드 아이.에이. 다임본 및 도레페질을 사용하여 알츠하이머 병을 치료하기 위한 조합 요법
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
RU2334514C1 (ru) 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2340342C2 (ru) 2006-12-07 2008-12-10 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
WO2008096791A1 (ja) 2007-02-07 2008-08-14 Astellas Pharma Inc. アシルグアニジン誘導体
DE102007009264A1 (de) 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen
RU2338745C1 (ru) 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
EP2145887B1 (en) 2007-04-05 2016-04-27 Alla Chem, LLC. Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-b]indoles, methods for the production and use thereof
CA2688327A1 (en) 2007-05-25 2008-12-04 Medivation Neurology, Inc. Methods and compositions for stimulating cells
RU2338533C1 (ru) 2007-06-28 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
JP2010535220A (ja) 2007-08-01 2010-11-18 メディベイション ニューロロジー， インコーポレイテッド 抗精神病用の併用療法剤を使用する統合失調症の治療のための方法および組成物
WO2009039420A1 (en) 2007-09-21 2009-03-26 Medivation Neurology, Inc. Methods and compositions for treating neuronal death mediated ocular diseases
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
JP5366211B2 (ja) 2007-12-18 2013-12-11 国立大学法人富山大学 アルドース還元酵素阻害活性を有する縮合三環化合物
JP2011507835A (ja) 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2009111540A1 (en) 2008-03-04 2009-09-11 Medivation Neurology, Inc. Methods for preparing pyridylethyl-substituted carbolines
BRPI0909040B8 (pt) * 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
WO2009120717A2 (en) 2008-03-24 2009-10-01 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
PE20091820A1 (es) 2008-03-24 2009-12-10 Medivation Technologies Inc Compuestos heterociclicos con uniones puente y metodos para usarlos
CL2009000731A1 (es) 2008-03-27 2009-05-15 Gruenenthal Gmbh Compuestos derivados de ciclohexano espirociclicos sustituidos, composicion farmaceutica que contiene a dicho compuesto y su uso como moduladores del receptor de opioides µ y el receptor orl-1 para tratar el dolor, ansiedad, depresion, epilepsia, alzheimer, abuso de alcohol, hipertension, anorexia, obesidad y diarrea.
WO2009135091A1 (en) 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
US8211930B2 (en) * 2008-05-20 2012-07-03 Astrazeneca Ab Phenyl and benzodioxinyl substituted indazoles derivatives
US20100029706A1 (en) 2008-07-30 2010-02-04 Edison Parmaceuticals, Inc. a Delaware Corporation HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
AU2009308706C1 (en) * 2008-10-31 2016-01-21 Medivation Technologies, Inc. Pyrido (4,3-b) indoles containing rigid moieties
AR073924A1 (es) 2008-10-31 2010-12-09 Medivation Technologies Inc Azepino[4, 5-b]indoles, una composicion farmaceutica y kits que los comprenden y su uso en la modulacion de un receptor de histamina.
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8604074B2 (en) 2009-01-09 2013-12-10 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
WO2011019417A1 (en) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b] indoles and methods of use
CN102480955B (zh) 2009-04-29 2015-08-05 梅迪维新技术公司 吡啶并[4,3-b]吲哚类和使用方法
WO2011014695A1 (en) 2009-07-29 2011-02-03 Medivation Technologies, Inc. New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use
CA2775129A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
CA2775216A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
CN102711468B (zh) 2009-09-23 2014-07-09 梅迪维新技术公司 吡啶并[4，3-b]吲哚化合物及其使用方法
WO2011038163A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
WO2011103433A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103487A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103448A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Methods and compositions for treating psychotic disorders using antipsychotic combination therapy
WO2012006419A2 (en) 2010-07-07 2012-01-12 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US8815843B2 (en) 2011-02-18 2014-08-26 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012112965A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US20150315188A1 (en) 2012-08-22 2015-11-05 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
AU2012388221B2 (en) 2012-08-24 2017-08-31 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds

Also Published As

Publication number Publication date
CL2009000724A1 (es) 2009-05-29
WO2009120717A2 (en) 2009-10-01
US9260429B2 (en) 2016-02-16
US9469641B2 (en) 2016-10-18
WO2009120717A3 (en) 2009-12-03
JP2014051526A (ja) 2014-03-20
EP2280968A2 (en) 2011-02-09
JP5748240B2 (ja) 2015-07-15
US20130131077A1 (en) 2013-05-23
CN102083830B (zh) 2014-11-12
AU2009228398A1 (en) 2009-10-01
JP5679538B2 (ja) 2015-03-04
TWI443098B (zh) 2014-07-01
BRPI0906244A2 (pt) 2015-06-30
US20090270412A1 (en) 2009-10-29
JP2011515482A (ja) 2011-05-19
US8338447B2 (en) 2012-12-25
US20130190323A1 (en) 2013-07-25
CN102083830A (zh) 2011-06-01
CA2719412A1 (en) 2009-10-01
AR071285A1 (es) 2010-06-09
US20130184306A1 (en) 2013-07-18
AU2009228398B2 (en) 2014-07-03
TW201000478A (en) 2010-01-01
HK1158636A1 (en) 2012-07-20
CN104387382A (zh) 2015-03-04
US20130079352A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
PE20091717A1 (es) Pirido[3,4-b] indoles como moduladores de receptores de histamina
PE20091346A1 (es) Compuestos tretraciclicos como moduladores de un receptor aminergico acoplado a la proteina g
AR072042A1 (es) Compuestos de 2,3,4,5-tetrahidro-1h-pirido(4,3-b)indol y metodos de uso de los mismos
AR094225A1 (es) Peptidos como agonistas de oxitocina
MA33783B1 (fr) Procédé de préparation de méthyl -{4,6-diamino-2-[1-(2-fluorobenzyl)- 1h-pyrazolo[3,4-b]pyridino-3-yl] pyrimidino-5-yl} méthylcarbamate et d'épuration de ce composé pour son utilisation en tant qu'agent pharmaceutique
NO20081476L (no) Substituerte benzimidazoler og fremgangsmater for fremstilling
EA201591204A3 (ru) Новые хиральные n-ацил-5,6,7,(8-замещенные)-тетрагидро-[1,2,4]триазоло[4,3-а]пиразины как селективные антагонисты рецептора nk-3, фармацевтическая композиция, способы применения при нарушениях, опосредованных nk-3 рецепторами, и их хиральный синтез
ECSP056218A (es) Metodo para la produccion de compuestos de 3-aryl-butil-amina substituidos.
PE20090158A1 (es) Dihidro y tetrahidro oxazolopirimidinonas sustituidas y preparaciones de las mismas
CO6410295A2 (es) Derivados de indol como antagonistas del receptor crth2
PE20080065A1 (es) Compuestos derivados de bencimidazol como moduladores del receptor vainilloide vr1
ATE469144T1 (de) Substituierte pyridonverbindungen und anwendungsverfahren
MX342288B (es) Proceso para producir compuestos de cicloalquilcarboxamido-indol.
ECSP077848A (es) Compuestos espiroheterocíclicos y sus usos como agentes terapéuticos
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
AR060647A1 (es) Derivados de piperidina con actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarinico, composiciones farmaceuticas que los comprenden, el uso de los mismos para la fabricacion de medicamentos para el tratamiento de afecciones pulmonares, metodos para preparar estos der
PE20141556A1 (es) Derivados de etinilo como moduladores alostericos de mglur5
PE20150671A1 (es) Antagonistas del receptor de 5-ht3
UA93209C2 (ru) Комбинация снотворного агента продолжительного действия эпливансерина и снотворного агента короткого действия золпидема
CL2012000263A1 (es) Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.
AR093042A1 (es) Derivados de etinilo
CO5590916A2 (es) Dicetopiperacinas sustituidas como antagonistas de oxitocina
CY1110688T1 (el) Διεργασια για την παρασκευη καρβεδιλολης και εναντιομερων αυτης
AR083595A1 (es) Derivados de indol y el proceso para su preparacion
NO20091675L (no) Eterderivatbaserte dobbeltvirkende modulatorer pa 5-HT2A og D3 receptorer

Legal Events

Date Code Title Description
FD Application declared void or lapsed